サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1392530

がん免疫療法の世界市場レポート 2024年

Cancer Immunotherapy Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
がん免疫療法の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

がん免疫療法の市場規模は近年急速に拡大しています。2023年の978億8,000万米ドルから2024年には1,109億1,000万米ドルへ、CAGR13.3％で拡大します。実績期間の成長は、がんの有病率の上昇、従来の治療法に対する免疫療法の採用の増加、標的疾患開発のための研究開発活動の活発化、新しい治療法の効果と精度の向上、従来のがん治療の限界に対する認識の高まりに起因しています。

がん罹患率の増加は、がん免疫療法市場を推進すると予想されます。世界のがん罹患数の増加要因としては、タバコ、アルコール、肥満、座りがちなライフスタイル、環境要因などが挙げられます。このようながん患者の増加は、がん免疫療法に対する需要を押し上げると予想されます。例えば、ベルギーに本部を置く欧州委員会の共同研究センターである欧州連合科学ハブによると、2023年10月、新たながん患者はその前の2年間で2.3％増加し、2022年には274万人に達しました。同様に、がんによる死亡者数も過去2年間で2.4％増加しています。したがって、がん罹患率の増加は、予測期間中にがん免疫療法の需要を押し上げると予想されます。

バイオシミラーの増加により、がん免疫療法市場の成長は今後数年で促進されると予想されます。バイオシミラーとは、既存の承認生物学的製剤（参照製剤）と非常によく似た生物学的医療製品であり、参照製剤と安全性、有効性、品質において臨床的に重要な差異がないように設計されています。バイオシミラーは、治療へのアクセスを高め、競争を刺激し、価格を下げ、がん患者により持続可能で多様な治療選択肢を提供するため、がん免疫療法において大きな可能性を秘めています。例えば、米国のバイオ医薬品会社であるアムジェン社によると、2022年第2四半期時点でFDAのバイオシミラー開発プログラムに登録されたバイオシミラー医薬品は96品目であり、70％近く増加しています。したがって、バイオシミラーの出現が増加していることががん免疫療法市場を牽引しています。

北米は、2023年のがん免疫療法市場において最大の地域であり、予測期間においても最も急成長する地域となる見込みです。がん免疫療法市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 がん免疫療法市場の特徴

第3章 がん免疫療法市場の動向と戦略

第4章 がん免疫療法市場- マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界のがん免疫療法市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年から2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 がん免疫療法市場セグメンテーション

  • 世界のがん免疫療法市場、製品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • モノクローナル抗体
  • チェックポイント阻害剤
  • 免疫調節剤
  • ワクチン
  • 細胞治療
  • 世界のがん免疫療法市場、用途別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 肺がん
  • 乳がん
  • 結腸直腸がん
  • 黒色腫
  • 前立腺がん
  • 多発性骨髄腫
  • 世界のがん免疫療法市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 病院
  • がん研究センター
  • クリニック

第7章 がん免疫療法市場の地域および国分析

  • 世界のがん免疫療法市場、地域別、実績および予測、2018年から2023年、2023年から2028年まで、2033年まで
  • 世界のがん免疫療法市場、国別、実績および予測、2018年から2023年、2023年から2028年まで、2033年まで

第8章 アジア太平洋のがん免疫療法市場

  • 概要
  • 地域情報、COVID-19症の影響、市場情報、背景情報、政府の取り組み、規制、規制機関、主要団体、課税額、法人税構造、投資、主要企業
  • 製品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 用途別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第9章 中国のがん免疫療法市場

第10章 インドのがん免疫療法市場

第11章 日本のがん免疫療法市場

第12章 オーストラリアのがん免疫療法市場

第13章 インドネシアのがん免疫療法市場

第14章 韓国のがん免疫療法市場

第15章 西欧のがん免疫療法市場

  • 概要
  • 製品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 用途別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第16章 英国のがん免疫療法市場

第17章 ドイツのがん免疫療法市場

第18章 フランスのがん免疫療法市場

第19章 イタリアのがん免疫療法市場

第20章 スペインのがん免疫療法市場

第21章 東欧のがん免疫療法市場

  • 概要
  • 製品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 用途別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第22章 ロシアのがん免疫療法市場

第23章 北米のがん免疫療法市場

  • 概要
  • 製品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 用途別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第24章 米国のがん免疫療法市場

第25章 カナダのがん免疫療法市場

第26章 南米のがん免疫療法市場

  • 概要
  • 製品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 用途別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第27章 ブラジルのがん免疫療法市場

第28章 中東のがん免疫療法市場

  • 概要
  • 製品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 用途別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第29章 アフリカのがん免疫療法市場

  • 概要
  • 製品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 用途別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第30章 がん免疫療法市場の競合情勢と企業プロファイル

  • がん免疫療法市場の競合情勢
  • がん免疫療法市場の企業プロファイル
    • Amgen Inc.
    • AstraZeneca PLC
    • F. Hoffmann-La Roche Ltd
    • Bayer AG
    • Eli Lilly and Company

第31章 世界のがん免疫療法市場の競合ベンチマーキング

第32章 世界のがん免疫療法市場競争ダッシュボード

第33章 がん免疫療法市場における主要な合併と買収

第34章 がん免疫療法市場の将来展望と可能性分析

第35章 付録

目次
Product Code: r10218

“Cancer Immunotherapy Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer immunotherapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer immunotherapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The cancer immunotherapy market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Product: Monoclonal Antibodies; Checkpoint Inhibitors; Immunomodulators; Vaccines; Cell Therapy
  • 2) By Application: Lung Cancer; Breast Cancer; Colorectal Cancer; Melanoma; Prostate Cancer; Multiple Myeloma
  • 3) By End User: Hospitals; Cancer Research Centers; Clinics
  • Companies Mentioned: Amgen Inc.; AstraZeneca PLC; F. Hoffmann-La Roche Ltd; Bayer AG; Eli Lilly and Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Cancer immunotherapy refers to a type of cancer therapy that strengthens your body's defenses against the disease. Your body's immune system aids in the defense against infections and other disorders. White blood cells, organs, and lymphatic system tissues make up this substance. Cancer immunotherapy comes in various forms, such as cytokines and vaccines, adoptive cell therapies, oncolytic viruses, tumor-infecting viruses, and others.

The main types of products of cancer immunotherapy are monoclonal antibodies, checkpoint inhibitors, immunomodulators, vaccines, and cell therapy. Monoclonal antibodies are man-made proteins that function in the immune system such as human antibodies. Cancer immunotherapy is used to treat lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, and multiple myeloma. These are used in hospitals, cancer research centers, and clinics.

The cancer immunotheraphy market research report is one of a series of new reports from The Business Research Company that provides cancer immunotheraphy market statistics, including cancer immunotheraphy industry global market size, regional shares, competitors with a cancer immunotheraphy market share, detailed cancer immunotheraphy market segments, market trends and opportunities, and any further data you may need to thrive in the cancer immunotheraphy industry. This cancer immunotheraphy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cancer immunotherapy market size has grown rapidly in recent years. It will grow from $97. 88 billion in 2023 to $110. 91 billion in 2024 at a compound annual growth rate (CAGR) of 13. 3%. The growth in the historic period can be attributed to rising prevalence of cancer, increased adoption of immunotherapy over traditional therapy, growing r&d activities for the development of targeted diseases, increased effectivity and accuracy of newer therapies, growing recognition of the limitations of traditional cancer treatments. .

The cancer immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $175. 39 billion in 2028 at a compound annual growth rate (CAGR) of 12. 1%. The growth in the forecast period can be attributed to increasing approval of novel immunotherapies for cancer treatment, growing demand for personalized medicine, rising cases of people being detected with cancer, increasing investment in clinical trials to introduce cutting-edge treatments, growing awareness about cancer immunotherapy. Major trends in the forecast period include emergence of adoptive cell therapies, including car-t cells, exploration of oncolytic viruses in cancer immunotherapy, development of personalized cancer vaccines, utilization of artificial intelligence in immunotherapy research, increasing emphasis on real-world evidence and patient outcomes in treatment decisions.

The rise in cancer incidence is expected to propel the cancer immunotherapy market. The factors contributing to the growth in cancer cases across the globe include tobacco, alcohol, obesity, a sedentary lifestyle, and environmental factors. This growth in cancer cases is expected to boost demand for cancer immunotherapies, as patients are increasingly investing in medical treatments with greater recovery and minimal pain. For instance, in October 2023, according to the European Union Science Hub, a Belgium-based European Commission's Joint Research Centre, new cancer cases increased by 2. 3% during the preceding two years, reaching 2. 74 million in 2022. Similarly, cancer fatalities increased by 2. 4% during the preceding two years. Therefore, the increase in cancer incidence is expected to boost demand for cancer immunotherapy during forecast period.

The increasing emergence of biosimilars is expected to propel the growth of the cancer immunotherapy market in the coming years. Biosimilars are biological medical products that are very similar to an existing authorized biological drug (the reference product) and are designed to have no clinically significant variations in terms of safety, effectiveness, and quality from the reference product. Biosimilars have great potential in cancer immunotherapy because they increase treatment accessibility, stimulate competition, lower prices, and provide more sustainable and diverse therapeutic alternatives for cancer patients. For instance, in 2022, according to Amgen Inc., a US-based biopharmaceutical company, the FDA reported 96 proposed biosimilar drugs registered in the FDA's Biosimilar Development Program as of Q2 2022, a nearly 70% increase. Therefore, the increasing emergence of biosimilars is driving the cancer immunotherapy market.

Advanced technologies used in cancer immunotherapy are a key trend gaining popularity in the cancer immunotherapy market. There has been a surge of new technologies and various therapies to help the immune system identify and attack tumors using different therapies and technologies such as immuno-oncology, cryoablation, bone marrow transplant, and radiation therapy. These technologies can make a significant difference in cancer treatment and cure. For instance, in October 2022, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, announced that it had received approval for its Capivasertib in combination with Faslodex. This drug is a cancer immunotherapeutic developed for the treatment of breast cancer and is effective in following recurrence or advancement on or after endocrine therapy in locally progressed or metastatic breast cancer with low or negative human epidermal growth factor receptor 2 (HER2).

Major companies operating in the cancer immunotherapy market are focusing on developing innovative products, such as Imjudo in combination with Imfinzi, to better meet the needs of their existing consumers. Imjudo, a combination of Imfinzi (durvalumab) and tremelimumab, is a possible dual immune checkpoint inhibitor in cancer immunotherapy. For instance, in October 2022, AstraZeneca Plc, a UK-based biotechnology and pharmaceutical company, announced the approval of Imjudo and Imfinzi for the treatment of unresectable hepatocellular carcinoma (HCC). The STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab) refers to the innovative dose and schedule of the combination, which involves a single dose of the anti-CTLA-4 antibody Imjudo 300mg combined with the anti-PD-L1 antibody Imfinzi 1500mg followed by Imfinzi every four weeks.

In August 2021, Bayer AG, a Germany-based pharmaceutical and biotechnology company, acquired Vividion Therapeutics, Inc., for an amount of $1. 5 billion. With this acquisition, Bayer increases its drug discovery and research expertise, develops new modalities, new chemoproteomic screening technology, a data portal, and a chemistry library in cancer immunotherapeutics. Vividion Therapeutics, Inc., is a US-based biotechnology company specializing in cutting-edge discovery tools so that cancer and immunological illnesses such as cancer can be treated precisely while also gaining access to high-value targets that have previously been unreachable.

Major companies operating in the in the cancer immunotherapy market report are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, 3D Signatures Inc., Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, Kura Oncology Inc., MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Pulse Biosciences Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc.

North America was the largest region in the cancer immunotherapy market in 2023 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cancer immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The cancer immunotherapy market includes revenues earned by entities by helping the immune system fight cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Cancer Immunotherapy Market Characteristics

3. Cancer Immunotherapy Market Trends And Strategies

4. Cancer Immunotherapy Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Cancer Immunotherapy Market Size and Growth

  • 5.1. Global Cancer Immunotherapy Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Cancer Immunotherapy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Cancer Immunotherapy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Cancer Immunotherapy Market Segmentation

  • 6.1. Global Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Monoclonal Antibodies
  • Checkpoint Inhibitors
  • Immunomodulators
  • Vaccines
  • Cell Therapy
  • 6.2. Global Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Multiple Myeloma
  • 6.3. Global Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Cancer Research Centers
  • Clinics

7. Cancer Immunotherapy Market Regional And Country Analysis

  • 7.1. Global Cancer Immunotherapy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Cancer Immunotherapy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Cancer Immunotherapy Market

  • 8.1. Asia-Pacific Cancer Immunotherapy Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8. 4. Asia-Pacific Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Cancer Immunotherapy Market

  • 9.1. China Cancer Immunotherapy Market Overview
  • 9.2. China Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9. 4. China Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Cancer Immunotherapy Market

  • 10.1. India Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Cancer Immunotherapy Market

  • 11.1. Japan Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.2. Japan Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Cancer Immunotherapy Market

  • 12.1. Australia Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Cancer Immunotherapy Market

  • 13.1. Indonesia Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Cancer Immunotherapy Market

  • 14.1. South Korea Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.2. South Korea Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Cancer Immunotherapy Market

  • 15.1. Western Europe Cancer Immunotherapy Market Overview
  • 15.2. Western Europe Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15. 4. Western Europe Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Cancer Immunotherapy Market

  • 16.1. UK Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Cancer Immunotherapy Market

  • 17.1. Germany Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Cancer Immunotherapy Market

  • 18. 5. France Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18. 6. France Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18. 7. France Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Cancer Immunotherapy Market

  • 19. 9. Italy Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.10. Italy Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.11. Italy Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Cancer Immunotherapy Market

  • 20.13. Spain Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.14. Spain Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.15. Spain Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Cancer Immunotherapy Market

  • 21.1. Eastern Europe Cancer Immunotherapy Market Overview
  • 21.2. Eastern Europe Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21. 4. Eastern Europe Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Cancer Immunotherapy Market

  • 22.1. Russia Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Cancer Immunotherapy Market

  • 23.1. North America Cancer Immunotherapy Market Overview
  • 23.2. North America Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23. 4. North America Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Cancer Immunotherapy Market

  • 24.1. USA Cancer Immunotherapy Market Overview
  • 24.2. USA Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24. 4. USA Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Cancer Immunotherapy Market

  • 25.1. Canada Cancer Immunotherapy Market Overview
  • 25.2. Canada Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25. 4. Canada Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Cancer Immunotherapy Market

  • 26.1. South America Cancer Immunotherapy Market Overview
  • 26.2. South America Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26. 4. South America Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Cancer Immunotherapy Market

  • 27.1. Brazil Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Cancer Immunotherapy Market

  • 28.1. Middle East Cancer Immunotherapy Market Overview
  • 28.2. Middle East Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28. 4. Middle East Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Cancer Immunotherapy Market

  • 29.1. Africa Cancer Immunotherapy Market Overview
  • 29.2. Africa Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29. 4. Africa Cancer Immunotherapy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Cancer Immunotherapy Market Competitive Landscape And Company Profiles

  • 30.1. Cancer Immunotherapy Market Competitive Landscape
  • 30.2. Cancer Immunotherapy Market Company Profiles
    • 30.2.1. Amgen Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1. 4. Financial Performance
    • 30.2.2. AstraZeneca PLC
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2. 4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche Ltd
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3. 4. Financial Performance
    • 30.2. 4. Bayer AG
      • 30.2. 4.1. Overview
      • 30.2. 4.2. Products and Services
      • 30.2. 4.3. Strategy
      • 30.2. 4. 4. Financial Performance
    • 30.2. 5. Eli Lilly and Company
      • 30.2. 5.1. Overview
      • 30.2. 5.2. Products and Services
      • 30.2. 5.3. Strategy
      • 30.2. 5. 4. Financial Performance

31. Global Cancer Immunotherapy Market Competitive Benchmarking

32. Global Cancer Immunotherapy Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Cancer Immunotherapy Market

34. Cancer Immunotherapy Market Future Outlook and Potential Analysis

  • 34.1 Cancer Immunotherapy Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Cancer Immunotherapy Market In 2028 - Segments Offering Most New Opportunities
  • 34. 3 Cancer Immunotherapy Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35. 4. Research Inquiries
  • 35. 5. The Business Research Company
  • 35. 6. Copyright And Disclaimer